MEMPHASYS LIMITED.

INVESTOR PRESENTATION - MEMPHASYS LIMITED.

ASX:MEM

MEMPHASYS LIMITED.

Health Care

Memphasys Ltd (ASX: MEM) is an Australian publicly-listed bio-separations company developing and commercialising innovative separation techniques based on the Company's proprietary membrane technology. Memphasys’ first application of this technology platform is now being commercialised – the separation of the ‘best’ sperm from a semen sample for use in human in vitro fertilisation (IVF).

Market Cap

105.56m

Price at Close

$0.14

4w avg. Volume

2.37m

4w avg. Turnover

$268.60k

Announcements
announcementt+2 movementdate
  • Performance rights vest on first market entry into Canada

    Issued Capital

  • +36.21%

    09 Jul 2020

+36.21%

09 Jul 2020
  • Cancellation of options

    Issued Capital

  • 0.00%

    05 Jul 2020

0.00%

05 Jul 2020
  • Securities Trading Policy

    Other

  • +2.00%

    02 Jul 2020

+2.00%

02 Jul 2020
  • MEM virtual presentation investor webinar

    Other

  • +3.85%

    25 Jun 2020

+3.85%

25 Jun 2020
  • MEM presentation Commercialising the Felix Device

    Periodic Reports

  • +3.85%

    25 Jun 2020

+3.85%

25 Jun 2020
  • Felix device commercialisation update

    Periodic Reports

  • -3.39%

    15 Jun 2020

-3.39%

15 Jun 2020
  • Trading on open market German stock exchanges

    Other

  • -10.29%

    11 May 2020

-10.29%

11 May 2020
  • Initial Director's Interest Notice

    Shareholder Details

  • -11.63%

    13 Mar 2020

-11.63%

13 Mar 2020
  • Final Director's Interest Notice

    Shareholder Details

  • -11.63%

    13 Mar 2020

-11.63%

13 Mar 2020
  • Director Appointment/Resignation

    Company Administration

  • -8.89%

    12 Mar 2020

-8.89%

12 Mar 2020
Market Data

Current Price

$0.14

52WK HIGH

$0.145

52WK LOW

$0.033

1YR RETURN

+169.23%

1YR RETURN VS. SECTOR

+7.20%

90 DAY RETURN

+112.12%

ASX RANK

722

/2,032

SECTOR RANK

2

/9

SHARES OUTSTANDING

753.97m
ASX:MEM

MEMPHASYS LIMITED.

Health Care

Memphasys Ltd (ASX: MEM) is an Australian publicly-listed bio-separations company developing and commercialising innovative separation techniques based on the Company's proprietary membrane technology. Memphasys’ first application of this technology platform is now being commercialised – the separation of the ‘best’ sperm from a semen sample for use in human in vitro fertilisation (IVF).

Market Cap

105.56m

Price at Close

$0.14

4w avg. Volume

2.37m

4w avg. Turnover

$268.60k

ASX:MEM is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Ask Fresh

Archive
Contact Us

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

(03) 9028 2888

deals@freshequities.com

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.